Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

To get information on ANDA & Paragraph IV challenges

— Global head business team (API & generics), Netherlands

To identify patent expiry dates for Canada and the USA

— Pharmacy services, Canada

For loss of exclusivity information of drugs in Egypt, Saudi Arabia, Algeria, UAE

— Analyst, India

To research if drugs are still protected with patents or not

— Investment Analyst, France

To find patent expiration dates of small molecules in the next ten years

— Pharmaceutical product development, India

Generated: May 27, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,088,934

« Back to Dashboard

Which drugs does patent 8,088,934 protect, and when does it expire?


Patent 8,088,934 protects AMITIZA and is included in one NDA. There has been one Paragraph IV challenge on Amitiza.

This patent has thirty-nine patent family members in twenty-four countries.

Summary for Patent: 8,088,934

Title:Composition and method for stabilizing the same
Abstract: Disclosed is a novel composition comprising a novel bi-cyclic compound, which is expected to be pharmaceutically active, and a glyceride. The stability of the bi-cyclic compound can be improved significantly by dissolving the same in a glyceride.
Inventor(s): Ueno; Ryuji (Montgomery, MD), Habe; Tsuyoshi (Sasayama, JP)
Assignee: SUCAMPO AG (Zurich, CH)
Application Number:12/144,000
Patent Claim Types:
see list of patent claims		Compound;

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-002Apr 29, 2008RXYesNo8,088,934► SubscribeY
Sucampo Pharma Llc
AMITIZA
lubiprostone
CAPSULE;ORAL021908-001Jan 31, 2006RXYesYes8,088,934► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,088,934

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,097,649Composition and method for stabilizing the same► Subscribe
6,583,174 Composition and method for stabilizing the same► Subscribe
7,417,067Composition and method for stabilizing the same► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,088,934

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina026046► Subscribe
Argentina089848► Subscribe
Austria267189► Subscribe
Austria402925► Subscribe
Australia2004242503► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

For information on when certain branded drugs expire, and where

— Director of procurement for clinical trials, USA

To update my knowledge in several markets

— Marketing professional, Spain

For information on patented drugs and their generic versions

— Policy analyst, South Africa

To find patent expirations for active pharmaceuticals ingredients

— Drug formulator, Israel

To understand patent expirations of controlled substances

— Consulting, USA

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot